Brain back-up start-up ‘will be the death of users’

Nectome has said it will one day be capable of scanning the human brain and preserving it, perhaps running a deceased person’s mind as a computer simulation.

However, its current process requires a fresh brain.

The product is “100% fatal”, the team behind it told MIT Technology Review.

The company is backed by Y Combinator, an organisation that picks a group of new companies each year to fund and mentor in the hope they receive major funding further down the line.

According to the company’s website, Nectome claims it will one day be possible to survey the brain’s connectome – the neural connections within the brain – to such a detailed degree that it will be able to reconstruct a person’s memories even after they have died.

“Imagine a world where you can successfully map and pinpoint a specific memory within your brain,” the site reads.

“Today’s leading neuroscience research suggests that it is possible by preserving your connectome.”


Grant money

Nectome will be part of Y Combinator’s demo days next week – an event where start-ups pitch their new companies to an audience of investors and journalists.

Previous Y Combinator firms include Dropbox and AirBnB.

The firm is also backed by a $960,000 (£687,000) grant from the US National Institute of Mental Health, which said it saw a “commercial opportunity” in brain preservation.

According to MIT Technology Review, the team has consulted lawyers familiar with California’s relatively new laws on dignified end-of-life measures.

The company plans to focus on working with terminally ill people in the testing phase.

The company uses an embalming process to preserve minute details of the brain in microscopic detail.

Its work won a prize for furthering the field of brain preservation when it tried the method on a rabbit.

Taking that further, the team said it had already attempted its technique on a just-deceased woman in Portland, Oregon.

However, even a delay of just a couple of hours meant the brain was already badly damaged, it said.

The next stage is to find someone planning to die via doctor-assisted suicide.

To continue the link for you here


Statement from FDA Commissioner Scott Gottlieb, M.D.,

Some of my most important time as Commissioner is spent speaking directly to patients and their families about significant health issues that affect their lives, from the devastating opioid crisis to the current flu season. Overseeing a wide array of medical products, the U.S. Food and Drug Administration plays a vital role in providing consumers with up-to-date, evidence-based information to help them make the most informed medical decisions. The products we regulate touch people’s lives in meaningful ways.con-con-1

Last month I had the opportunity to meet with consumers who have been affected by the medical device Essure to listen and learn about their concerns. This device is used as a method of permanent birth control. The product’s manufacturer, Bayer, estimates that more than 750,000 women worldwide have received the device implant since it was first approved by global regulatory authorities. Some of the women I spoke to went on to develop significant medical problems that they ascribe to their use of the product. As a physician, I know that patients are uniquely positioned to provide feedback to the FDA about their experiences with currently available medical products, and I appreciated the thoughtful discussion. Ensuring the safety and effectiveness of medical products is paramount to the FDA and a core part of our consumer protection role. The FDA takes concerns about Essure very seriously.

I would like to outline the steps we’ve taken, to date, regarding this product, and the additional steps that are underway. I also want to reiterate my commitment to regularly communicating with patients and physicians about this device as more information is made available and additional steps are taken.

Since Essure’s approval in 2002, the agency has continued to monitor the product’s safety and effectiveness by reviewing the medical literature, clinical trial information, post-approval study data and medical device reports submitted to the agency. We convened a panel of medical experts in the fall of 2015 to provide us with advice on how we could better understand concerns about the device, such as patients who experienced abdominal pain, abnormal uterine bleeding and device migration.

In February 2016, we ordered the manufacturer of Essure, Bayer, to conduct a postmarketing (522) study to better evaluate the safety profile of this device when used in the real world. We also required a boxed warning to be added to the product labeling as well as a Patient Decision Checklist. The aim is to help make certain that a woman considering Essure receives and has full access to information about the benefits and risks of this type of device prior to undergoing treatment with this product.

As part of the FDA’s ongoing efforts to monitor Essure adverse events, we continue to review medical device reports submitted to our public database and provide updates about our ongoing analysis of the reports on our website. At the current time, the FDA is actively evaluating a significant collection of new medical device reports submitted to FDA on the Essure device. Of the nearly 12,000 reports received in 2017 for Essure, the majority were sent to the FDA in the last quarter of the year.

Detailed Statement enhanced here

Top 7 Ranking Signals: What REALLY Matters in 2018?

Every year it seems Google gives us a new ranking signal.

In 2014, HTTPS became a ranking signal.

In 2015, mobile usability became a ranking signal.

Then, 2016 shifted content development as RankBrain came onto the scene.

And, in 2017, there was a more significant push for more HTTPS websites.

Now, in 2018, mobile page speed looks to be the next big ranking signal to focus on.

All that said, John Mueller assures us that “awesomeness” is the key to ranking in Google.

But, with over 1 billion websites online today, how do you create awesomeness?

One thing I know for sure is that all of these ranking factors are all shaped to create a better, more awesome user experience.


With Google evaluating sites based on hundreds of ranking factors, knowing where to aim your SEO strategy in 2018 for the biggest bang might seem impossible.

But good news: Ranking signals are going to continue to adapt to the user.

This means that new SEO trends already surviving have roots in the current algorithm — and with a little creativity and SEO savvy, it’s entirely possible for you to rank well in 2018.

While ranking signals are far from limited to just seven, the factors highlighted in this post are ones I consider to be the most important for this year.

Here are the ranking factors that will really matter in 2018, and why.

1. Publish High-Quality Content

“I don’t need quality content on my website to rank,” said no one ever.

The quality of your website and blog content is still crucial for 2018. Content still reigns as king.

As Rand Fishkin pointed out in a Whiteboard Friday, content that is optimized for keywords still holds valuable SEO power.

Your content needs to provide valuable information. Creating pages with no real value can come back to haunt you, thanks to Google’s Panda and Fred algorithm updates.

Pages like this portal site.

Even big names like eBay and Apple aren’t worthy of the content crown. Thin content hurt both brands.

High-quality content is about creating pages that increase time on page, lower bounce rate, and provide helpful content for the user.

Blog pages like this and guides like this are the type of high-quality content search engines, and users want.

High-quality content pages must do more for today’s SEO than just be well-written and long-form. They also have to cover the following areas to increase their presence in SERPs:

Search Intent

Knowing users’ search intent is essential to creating pages that drive organic traffic.

CoSchedule saw a 594 percent increase in traffic by reshaping their SEO content strategy to be more aligned with searcher intent.

To understand what your target searchers intent is, you need to dive into your Google Analytics to see what users are looking for.

Reports like Site Search and User Flow can give you an idea of what your customers are searching for.


You can also view Search Analytics report in Google Search Console. This report will give you insights into what people are clicking on the SERPs to get to your site.

Keyword Research

Despite the word on the street that keyword research is not needed to rank, keyword research still supports quality content creation. Unlike traditional keyword research, today, keywords serve as a content creation roadmap.

Through competitor research and data mining, you can uncover keyword gems that have average search volume, but high click-through rate for your audience.

Check out how Chris Hornack, founder of Blog Hands, saw an 80 percent increase in traffic after performing keyword research.

So, as the industry continues to whisper about the negative impact of keyword research, you need to identify your primary keywords and bucket them into topics suited for your searcher.

Andrea Lehr, Brand Relationship Strategist at Fract, shares insights on how she buckets her keywords here.

Voice Search

According to Google,  72 percent of people who own a voice-activated speaker say that their devices are often used as part of their daily routine.

It’s evident that since the growth of AI assistants like Siri, Alexa, and Cortona, a new way of searching is coming.

Optimizing for the way people speak can feel like going to your first yoga class.

You’re looking around at what other people are doing, trying to breathe deeply while holding your lotus cup above your head, meanwhile, you’re just waiting for savasana. #Awkward.

I get it. And, Dawn Anderson does too. She offers some awesome tips on SEO for voice search, including thinking about how people ask questions and understanding local queries and intent.

And, Brian Dean recently shared his insights into optimizing for voice search after reviewing 10,000 Google Home results.

Rich Snippets

Rich snippets use schema to markup your text and data for better visibility in Google search results.

Rich snippets could mean photos or ratings on your result (which is standard for recipes) like this.

Rich snippets can increase your click-through rate and lower your bounce rate because it gives users more of a preview of your content before they click on it.

If SERPs are the front door to your business, your content pages are the interior, showing users that your website (and therefore, your products or services) are worth their time.

By building high-quality content for your website,  you create a warm and inviting place for your users and search engines to make themselves at home.

Continuation part here it goes

ICH Q10 -the ICH’s Pharmaceutical Quality System

The purpose for which the International Conference on Harmonization (ICH) has issued wide-ranging in ICH Q 10 guidelines is that they help individuals and organizations in the pharmaceutical industry avoid duplication of their work, especially in pharmaceutical research and product registration.

ichQ10PharmaceuticalQualitySystemReduction of double work is the important purpose

Putting in place greater harmonization in the area of pharmaceutical product registration by interpreting and applying technical ICH guidelines was the aim with which the ICH was launched in 1990.

The harmonization the ICH Q 10 aims to bring about seeks to reduce and possibly eliminate repetition of testing and reduce double work of research and development of new human medicines. It uses extensive guidelines to achieve this. These guidelines are given for all areas of ICH Q 10.

Quality Guidelines:

Related to the Quality area; these guidelines include crucial milestones such as doing stability studies, defining appropriate limits for impurities testing, and evolving a malleable approach to GMP risk management based pharmaceutical quality.

Safety Guidelines:

Relates to the safety aspect of carrying out research in the carcinogenic, genotoxic and repro toxic areas, which carry a high risk of danger.

Efficacy Guidelines:

To ensure efficacy in research, ICH guidelines cover areas such as the conduct, design, safety and reporting of clinical trials. Efficacy guidelines also include biotechnological processes and pharmacogenetics or genomics techniques, which are aimed at producing medicines that target disease better.

Multidisciplinary Guidelines:

These are guidelines are for areas left out of the Quality, Safety and Efficacy Guidelines. Core elements of this area of ICH Q 10 guidelines include ICH medical terminology (MedDRA), the Common Technical Document (CTD) and the development of Electronic Standards for the Transfer of Regulatory Information (ESTRI).

FDA inspection is not going to invite an FDA action such as a 483 or a Warning Letter

If there is one common cause for apprehension between the smallest and biggest, and the best known and least known organizations; it has to be an FDA inspection! Any organization that is subject to an FDA inspection has to get absolutely everything of everything about its activities right to a T, to such an extent that it should be sure simply all the time, through all its processes, that an FDA inspection is not going to invite an FDA action such as a 483 or a Warning Letter. This means compliance at its highest and lowest levels.


To simplify matters to an extent, the FDA has tried to be of some assistance to help in monitoring the conduct of all aspects of the conduct and reporting of organizations involved in FDA-regulated research. This has concretized in the form of the FDA’s Bioresearch Monitoring Program, or BIMO. This on-site inspection and data audit program can be used as a reference guide by industries in FDA-regulated research industries. Adherence to it is a yardstick for compliance with FDA regulations in the field.

In other words,compliance to the implementation requirements of the BIMO is a fair indicator of how well the organization comes out unscathed out of an FDA inspection. Meant for monitoring Clinical Investigators (CIs), the Institutional Review Boards (IRBs), Sponsors or Contract Research Organizations (CROs)/Monitors, and nonclinical laboratories; the BIMO spans quite a range of players in the FDA-regulated research.

What are the BIMO’s objectives?

The FDA’s Bioresearch Monitoring Program has two important objectives:

  • Protecting the welfare, rights and safety of human research subjects
  • Ensuring that the data collected by researchers is reliable and is of acceptable integrity and quality


What are the BIMO’s functions?The FDA’s Bioresearch Monitoring Program has a few functions, which research organizations that have to survive an FDA inspection could do well to comprehend. These include:

  • Clinical data auditing
  • Inspection of the ongoing clinical research
  • Subjecting nonclinical laboratories and IRBs to inspections
  • Taking steps to train, educate and implement the FDA’s Application Integrity Policy.

Understand the underlying causes that lead to an inspection

The key to passing an FDA inspection is to understand that there are strong reaons for which an FDA inspection happens. Research organizations that want to pass an FDA inspection have to get a grasp of the factors that prompt the FDA to inspect research. These include:

  • Introduction of a new technology
  • Introduction of a new product or an indication
  • Receipts of complaints by the FDA from aggrieved parties
  • CRO being a habitual non-complier

WHK hires top cyber security talent

Global online security exchange provider, WhiteHawk Limited (ASX:WHK) has announced that it has made a strategic investment in top cyber talent.

The company, which offers the first global online cyber security exchange which enables small-to-medium businesses to take smart action against cyber-crime and fraud, has made two new hires and promoted Antonio Crespo as Chief Information Officer.

Crespo joined WHK in 2017 as the company’s Director of Product Development and Services. He has expertise in security threat analysis and security product engineering, having gained experience at Computer Sciences Corporation and Security Risk Advisors prior to joining WHK. As CIO, Crespo will oversee the management and delivery of all customer facing WHK services, product lines, and business operations.


Soo Kim joins WHK as Director of Product Development from Accenture Federal Services. She brings more than 20 years’ experience in software engineering and technology strategy, having held senior positions at Accenture Federal Services, HP Enterprise Services, and TASC Inc. At WHK, Kim will lead the daily development, testing and advancement of the CyberPath Solution Engine and all data analytics efforts, to include the continuous improvement of the WHK online ecosystem.

Jason Beach has also joined the team as Senior Data Scientist, bringing recent data analytics and solution development experience from supporting customers such as Microsoft Corp, North Western Mutual Insurance, and US Departments of Treasury and Defense.

WHK also announced the promotion of Israel Villanueva, previously a WHK sales partner, who now joins as the Solutions Architect. Villanueva will work with and manage all cyber security vendors, and focus on how to tailor, market, price and deliver top products and services. He has over 12 years of VP and Account Executive experience in the marketing and sales of software and technology.

computer network backup_web

It’s worth noting that WHK is an early stage play and investors should seek professional financial advice if considering this company for their portfolio.

Executive Chair of WhiteHawk, Terry Roberts, commented on today’s announcement. “In a short period of time, Antonio has proven himself an insightful, driven, and results-oriented cyber businessman and I believe that he is well-suited for the role of CIO. I am also excited to welcome Soo and Jason to the team, both of whom are extremely talented and bring the level of expertise and innovation to ensure that our business and our website development move forward with efficiency and sophistication.”

He continued, “With the additional technical talent that we have been able to attract thanks to the investment of our shareholders, we are now able to start executing on our robust development plan which will, in turn, enable us to maximise value for our shareholders in the long term.”

to continue

Telstra launching London cybersecurity centre

Telstra has announced that it will be launching a Security Operations Centre (SOC) in London, with CEO Andy Penn telling ZDNet that cybersecurity is becoming critical for all businesses.

Speaking during Telstra’s first-half financial results call, Penn pointed towards the telco’s growing capabilities in security.

“During the half, we enhanced our cybersecurity services with the opening of two new Security Operations Centres in Melbourne and Sydney,” he said.


“We have plans to open a further Security Operations Centre this year in London. We have seen strong demand for our cybersecurity offerings in the context of a market where this is becoming an increasingly important issue for companies and boards.”

Penn told ZDNet that the London SOC will have the “same dynamic” as its Melbourne and Sydney centres, which operate virtually as one room with interaction between all of the operators.

“It builds up the ecosystem of the security capability that we have,” he told ZDNet.

“What it enables us to do is either directly for our customers, particularly the large enterprise customers, and/or in partnership with our customers, monitor all of their own in-house networks to make sure that we can identify the aberrant behaviour and the aberrant traffic, any malware, also effectively intervene quickly, and the security operations centres also have crisis management centres in conjunction with them, and it enables us to actually [interact] quickly with the customer, with the teams wherever they are in the world to really manage an incident if and when it occurs.”


The London SOC will also house around the same amount of workers as its Sydney and Melbourne centres, he told ZDNet, which see teams of around 25 people from its 500-strong cybersecurity expert base monitoring 24/7.

In regards to launching additional SOCs across the globe, Penn said Telstra has not yet formally announced any plans.

“The only thing I would say is that undoubtedly cybersecurity is becoming an increasingly critical and important issue for large companies and small companies for that matter, for boards, for chairmen of companies, for CEOs,” he told ZDNet.

“So we are only likely to see this demand increase, and of course it’s a global risk, so whilst obviously much of our focus is on Australian companies and also in the Asia-Pacific, we also have to protect our customers wherever they may be doing business.”

Also beyond standard fixed and mobile telco offerings is Telstra’s Internet of Things (IoT) business, which Penn said is continuing to grow, pointing to the acquisitions of MTData and VMtech and the launch of its Cat-M1 IoT network during the half.

Telstra’s IoT business is nearing AU$200 million in revenue, which he said makes Telstra “one of the most successful IoT businesses globally”.  Click the link to read the entire article.